Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

Jaafar Bennouna(Institut de Cancérologie de l'Ouest), Javier Sastre(Hospital Clínico San Carlos), Dirk Arnold(University Cancer Center Hamburg), Pia Österlund(Helsinki University Hospital), Richard Greil(Paracelsus Medical University), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Roger von Moos(Kantonsspital Graubünden), José María Viéitez(Hospital Universitario Central de Asturias), Olivier Bouché(Université de Reims Champagne-Ardenne), Christophe Borg(Centre Hospitalier Universitaire de Besançon), Claus-Christoph Steffens(Elbe Kliniken Stade-Buxtehude), Vicente Alonso-Orduña(Hospital Universitario Miguel Servet), C. Schlichting(Agaplesion Diakonieklinikum Rotenburg), Irmarie Reyes‐Rivera, Belguendouz Bendahmane(Roche (Switzerland)), Thierry André(Sorbonne Université), Stefan Kubicka(Reutlingen University)
The Lancet Oncology
November 15, 2012
Cited by 1,163Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis